Home › Triple-Negative Breast Cancer › NCT05115474
Study of Screening Brain MRIs in Stage IV Breast Cancer
RecruitingPhase 2
Phase II Study of Screening Brain MRIs in Stage IV Breast Cancer
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Histologic diagnosis of breast cancer with documentation of ER/PR/HER2 status * Radiographic evidence of stage IV extracranial diease having progressed past first line therapy in HR+/HER2- patients * Radiographic evidence of stage IV extracranial disease in TN and HER2+ patients * Age ≥ 18 * Life expectancy ≥ 6 months * Eastern Cooperative Oncology Group performance status 0 to 2 * Patients must be able to understand and the willingness to sign an informed consent for study procedures * Stated willingness to comply with all study procedures and availability for the duration of the study Exclusion Criteria: * Prior diagnosis or treatment of brain metastases or leptomeningeal disease * Patients with prior history of non-breast cancer malignancies should have no evidence of disease ≥ 2 years * Neurologic symptoms warranting standard screening brain MRI in the judgement of the treating physician at time of enrollment * Indications warranting brain MRI for other neurologic conditions at time of study entry * Contraindication towards MRI imaging with contrast * Chronic kidney disease stage IV or V or end stage renal disease
About the study
The study is a single arm, nonrandomized phase II prospective study, with the goal of investigating the role of screening brain MRIs in neurologically asymptomatic patients with metastatic breast cancer.
What is being tested
- Magnetic Resonance Imaging (diagnostic test)
Sponsor: H. Lee Moffitt Cancer Center and Research Institute · Participants: 170 · Started: Dec 21, 2021
Contact the study team
- Robin Dowell · Phone: 813-745-0393
Official record on ClinicalTrials.gov — NCT05115474
Locations in the U.S.
| Florida | Morton Plant Mease- Baycare, Clearwater |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.